APLS · As filed with the SEC
Apellis Pharmaceuticals income statement, by quarter
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue: | ||||||||
| Revenue | 268,295,000 | — | 458,578,000 | 178,494,000 | 166,797,000 | — | 196,830,000 | 199,685,000 |
| Licensing and other revenue | 76,285,000 | — | 280,823,000 | 7,107,000 | 16,897,000 | — | 20,259,000 | 20,549,000 |
| Product revenue, net | 192,010,000 | — | 177,755,000 | 171,387,000 | 149,900,000 | — | 176,571,000 | 179,136,000 |
| Operating expenses: | ||||||||
| Cost of sales | 40,547,000 | — | 24,531,000 | 13,626,000 | 34,360,000 | — | 33,557,000 | 23,100,000 |
| Research and development | 76,958,000 | — | 68,186,000 | 67,015,000 | 86,420,000 | — | 88,569,000 | 77,947,000 |
| Selling, general and administrative | 124,323,000 | — | 142,678,000 | 131,139,000 | 129,345,000 | — | 121,984,000 | 128,081,000 |
| Total operating expenses: | 241,828,000 | — | 235,395,000 | 211,780,000 | 250,125,000 | — | 244,110,000 | 229,128,000 |
| Net operating income/(loss) | 26,467,000 | — | 223,183,000 | (33,286,000) | (83,328,000) | — | (47,280,000) | (29,443,000) |
| Loss on extinguishment of development liability | — | — | — | — | — | — | — | (1,949,000) |
| Interest income | 2,914,000 | — | 4,376,000 | 2,607,000 | 2,658,000 | — | 2,889,000 | 3,184,000 |
| Interest expense | (10,317,000) | — | (11,279,000) | (11,152,000) | (11,049,000) | — | (12,532,000) | (9,359,000) |
| Other income/(expense), net | 88,000 | — | 37,000 | 146,000 | (165,000) | — | 70,000 | 24,000 |
| Net income/(loss) before taxes | 19,152,000 | — | 216,317,000 | (41,685,000) | (91,884,000) | — | (56,853,000) | (37,543,000) |
| Income tax expense | 496,000 | — | 602,000 | 466,000 | 341,000 | — | 592,000 | 114,000 |
| Net income/(loss) | 18,656,000 | — | 215,715,000 | (42,151,000) | (92,225,000) | — | (57,445,000) | (37,657,000) |
| Other comprehensive income/(loss): | ||||||||
| Unrealized gain/(loss) on pension plans | — | — | 137,000 | — | — | — | — | — |
| Foreign currency translation | (308,000) | — | 32,000 | 485,000 | 254,000 | — | 222,000 | 163,000 |
| Total other comprehensive income/(loss) | (308,000) | — | 169,000 | 485,000 | 254,000 | — | 222,000 | 163,000 |
| Comprehensive income/(loss), net of tax | 18,348,000 | — | 215,884,000 | (41,666,000) | (91,971,000) | — | (57,223,000) | (37,494,000) |
| Net income/(loss) per common share - basic | 0.15 | — | 1.71 | (0.33) | (0.74) | — | (0.46) | (0.3) |
| Net income/(loss) per common share - diluted | 0.15 | — | 1.67 | (0.33) | (0.74) | — | (0.46) | (0.3) |
| Weighted-average number of common shares used in net income/(loss) per common share - basic | 127,682,000 | — | 126,424,000 | 126,024,000 | 125,452,525 | — | 124,234,000 | 123,904,000 |
| Weighted-average number of common shares used in net income/(loss) per common share - diluted | 131,424,000 | — | 130,067,000 | 126,024,000 | 125,452,525 | — | 124,234,000 | 123,904,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.